	As of February 2019, relugolix is in phase III clinical trials for endometriosis and prostate cancer. It was approved for use for the treatment of uterine fibroids in Japan in January 2019. A New Drug Application of relugolix for uterine fibroids is expected to be submitted in the United States late 2019.